New lab test could speed development of new class of AIDS drugs

December 17, 2001

A fast, sensitive laboratory test that measures the molecular components involved during the critical moment when HIV infects a normal cell has been developed by researchers in the University of California, San Diego (UCSD) School of Medicine and VA San Diego Healthcare System.

Described in the December 2001 issue of the Journal of Biological Chemistry (JBC), the new test makes it possible to study and design new compounds to block the action of these molecular components before HIV can permanently infect a normal cell, causing it to manufacture more virus.

In recognition of the test as "groundbreaking work toward new pharmaceutical strategies to combat the virus that causes AIDS," the GlaxoSmithKline pharmaceutical company awarded UCSD's Richard Kornbluth, M.D., Ph.D., with a Drug Discovery and Development Award during a professional meeting Dec. 14 in Chicago. Kornbluth, who was senior author of the JBC article, is a UCSD associate professor of medicine and a researcher with the VA San Diego Healthcare System.

Kornbluth explains that once HIV enters a host cell's DNA, the cell becomes permanently infected after the virus splices its genes into the DNA of the host cell, a process known as "integration." Drugs now available to treat HIV-infected individuals work by inhibiting enzymes that contribute to the spread of HIV, but no drugs have yet been approved that prevent the virus from integrating its DNA into the host cell.

"If we can find a way to intercept HIV during the integration process, when HIV DNA is spliced into normal cells, we can stop it before the cell is permanently infected," Kornbluth says.

HIV drugs now used to treat patients inhibit reverse transcriptase and protease, two of the three enzymes that play a role in infection. Reverse transcriptase works after HIV has entered a host cell by copying the viruses RNA genome into a DNA form. Protease affects the structure of the virus by cutting viral proteins into short pieces that can be incorporated into new viruses.

The third enzyme, integrase, is part of a group of molecules called a preintegration complex (PIC) that promotes HIV integration into the host cell DNA. The entire PIC moves through a pore in the nucleus of the invaded cell, where integrase inserts genes from the viral DNA into the cell's chromosomes, which is required for the production of more HIV viruses by the infected cell.

The test developed in the Kornbluth lab will allow scientists and drug developers to search millions of chemical compounds for potential drugs that can inhibit any of the components required for the PIC to integrate, not just drugs that inhibit the enzyme integrase.

"The major way that pharmaceutical companies develop drugs is to screen collections of chemicals, anywhere from 100,000 to three million," Kornbluth says. "Our test will allow them to target the entire PIC which is the actual target a successful drug must attack. We believe that molecular components in the PIC, besides integrase, are critical to whether or not HIV is able to integrate into the host cell DNA."

In addition to its ability to look at the entire PIC, Kornbluth's test is considerably faster then a test developed in 1987, with results taking 2-3 hours, rather than 2-3 days. There's also increased volume 100 tests can be done in 2-3hours, compared to about 30 tests that were run over 2-3 days.
-end-
In addition to Kornbluth, authors of the article in JBC were Alexei Brooun, Ph.D., a post-doctoral fellow in Kornbluth's lab, and Douglas R. Richman, M.D., director of the UCSD AIDS Research Institute and professor of medicine and pathology, UCSD and VA San Diego Healthcare System.

The work was funded by the American Foundation for AIDS Research (amfAR), the National Institutes of Health, the State of California's Universitywide AIDS Research Program, the UCSD Center for AIDS Research, the Department of Veteran Affairs, and the Research Center on AIDS and HIV Infection of the VA San Diego Healthcare System.

The following news release and any accompanying images can be accessed on the web at: http://health.ucsd.edu/news/2001/12_17_Kornbluth.html

University of California - San Diego

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.